Featured Research

from universities, journals, and other organizations

New Drug For Deadly Infection Shows Favorable Results In Preliminary Trials

Date:
June 4, 1997
Source:
Johns Hopkins Children's Center
Summary:
A new drug may help prevent respiratory syncytial virus (RSV), which hospitalizes over 90,000 infants each year in the United States. Preliminary testing took place at Georgetown University Medical Center.

WASHINGTON, DC -- A new drug to prevent a form of pneumonia that kills 4,500 infants a year in the United States shows promise after preliminary clinical testing at Georgetown University Medical Center and nine other centers in the U.S.

The new drug, called MEDI-493, has undergone a double-blind, placebo controlled, dose escalation, multi-center, phase I/II trial evaluating important safety and pharmacological properties for treatment of respiratory syncytial virus in infants. MedImmune Inc. of Gaithersburg, MD, which supported this trial, has the exclusive worldwide marketing and manufacturing rights for MEDI-493. Respiratory syncytial virus (RSV) afflicts the underdeveloped lungs of premature infants, and is responsible for the hospitalization of 90,000 infants each year in the United States alone. The cost of treating a high-risk infant for RSV can be over $70,000.

Currently, a drug called RespiGam™ (Respiratory Syncytial Virus Immune Globulin Intravenous (Human)) is given to high-risk infants to prevent hospitalization due to RSV infection. At risk infants receive RespiGam™ once a month in a lengthy two to four hour infusion. RespiGam ™ is marketed in the U.S. by MedImmune in partnership with American Home Products Corporation.

MEDI-493 can be given more rapidly by infusion or by intra-muscular injection. If successful in phase III clinical trials, MEDI-493 has the potential to enhance patient care, reduce costs associated with drug administration and improve convenience for parents, physicians and nurses.

Dr. K.N. Siva Subramanian, the principal investigator in this study, presented the findings last month at the Pediatric Societies' Annual Meeting in Washington, DC.

# # # Commercialization of MEDI-493 will require prior approval from regulatory authorities, including the Food and Drug Administration in the United States. There can be no assurances that such approvals will be obtained.


Story Source:

The above story is based on materials provided by Johns Hopkins Children's Center. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins Children's Center. "New Drug For Deadly Infection Shows Favorable Results In Preliminary Trials." ScienceDaily. ScienceDaily, 4 June 1997. <www.sciencedaily.com/releases/1997/06/970604092145.htm>.
Johns Hopkins Children's Center. (1997, June 4). New Drug For Deadly Infection Shows Favorable Results In Preliminary Trials. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/1997/06/970604092145.htm
Johns Hopkins Children's Center. "New Drug For Deadly Infection Shows Favorable Results In Preliminary Trials." ScienceDaily. www.sciencedaily.com/releases/1997/06/970604092145.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins